• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CanSino vaccine loses efficacy to 50% over 5-6 months

kiwibird

Editor, Senior Moderator
https://www.theguardian.com/world/l...son-and-johnson-vaccine-fails-quality-control

China?s CanSino Biologics has said that the efficacy rate for its single-dose Covid vaccine may fall over time although it should still have a rate of 50% or more five to six months after inoculation.


A second shot given to trial participants six months after their first injection could offer substantial protection, Zhu Tao, CanSinoBIO?s chief scientific officer, said in an online presentation late yesterday reported by Reuters.

The vaccine has been approved in China, Pakistan, Hungary and Mexico, and CanSinoBIO is also planning a clinical trial in China for an inhaled version of the vaccine.

?A booster shot six months later led to a seven times to 10-times increase in neutralising antibody levels, so we expect in this case efficacy could reach over 90%,? Zhu said, though he cautioned more clinical trial data was needed for more precise estimates.
 
Back
Top Bottom